D-1262-2020 Class III Terminated

Recalled by The Harvard Drug Group — Livonia, MI

FDA drug recall D-1262-2020 was initiated by The Harvard Drug Group on Apr 24, 2020 and is designated Class III. Reason for recall: Failed dissolution specifications: Low stage 3 results obtained for dissolution during routine stability testing. The recall status is terminated (terminated Aug 19, 2022). Affected quantity: 678 cartons.

Recall details

Product Type
Drugs
Report Date
May 20, 2020
Initiation Date
Apr 24, 2020
Termination Date
Aug 19, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
678 cartons

Product description

Memantine Hydrochloride Extended-Release Capsules, 28 mg, 100 capsules per unit dose cartons, Rx only, Manufactured by: Lupin Limited, Pithampur (M.P.)-454 775, India; Distributed by: Major Pharmaceuticals, 17177 N Laurel Park Dr., Suite 233, Livonia, MI 47152 USA. NDC: 0904-6735-61

Reason for recall

Failed dissolution specifications: Low stage 3 results obtained for dissolution during routine stability testing.

Distribution pattern

AL, FL, IA, NY, OH, TX

Code information

Lot #: M02199D, M02246D, Exp 5/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1262-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1262-2020. Report a data issue: hello@regdatalab.com.